Article History
Accepted: 12 May 2022
First Online: 14 June 2022
Competing interests
: R.S.H. is a consultant for AstraZeneca, Merck, Genentech/Roche, Lilly, Bristol-Myers Squibb, and a scientific adviser of NextCure. L.C. is a scientific founder, consultant and/or board member of NextCure, Junshi, Tayu, Normunity, Zai Lab, Tpioneer, Vcanbio and GenomiCare; and has sponsored research funds from NextCure, Normunity and DynamiCure. The other authors declare no competing interests.